News

For the year ended December 31, 2008, the company posted a net loss of C$41.39 million, or C$0.45 per share, compared to a net loss of C$38.92 million,

Indian scientists from the past decade, under fewer restrictions, pushed ahead with their own research. “The future impact that I see of the reversal of the Bush administration

Under the terms of the agreement, Arabian Medical Marketing (AMCO) will provide direct sales and service support for Intelligent Hospital Systems’s (IH Systems’s) Robotic IV Automation (RIVA) system

Charles Wilhelm, president and COO of Karl Storz, said: “Karl Storz has had a marketing agreement with Global Care Quest since 2006. Our acquisition of the company now

The program is intended to produce therapeutic molecules for the treatment of inflammatory airway diseases including rhinitis, asthma and chronic obstructive pulmonary disease (COPD). The trial data showed

Morphotek, a subsidiary of Eisai Corporation of North America, has reported that the FDA has agreed to and approved the design of a single, pivotal, Phase III clinical

China Biologic Products, a plasma-based pharmaceutical company, has reported that its indirect majority owned subsidiary, Shandong Taibang Biological Products, has completed the government approval process for the transfer

Calixa Therapeutics, a biopharmaceutical company, has reported positive results from a Phase I trial of intravenous CXA-101, a novel cephalosporin antibiotic with excellent in vitro anti-pseudomonal activity. According

The approval was based on results of two randomized, double-blind, active-controlled, multinational studies (studies 308 and 313) that evaluated Tygacil for the treatment of community-acquired bacterial pneumonia (CABP)